Scholz Michael, Ulbrich Holger K, Soehnlein Oliver, Lindbom Lennart, Mattern Andreas, Dannhardt Gerd
Institute of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Johannes Gutenberg-University, Staudingerweg 5, DE-55128 Mainz, Germany.
Bioorg Med Chem. 2009 Jan 15;17(2):558-68. doi: 10.1016/j.bmc.2008.11.074. Epub 2008 Dec 6.
Three series of non-steroidal anti-inflammatory drugs (NSAIDs) inhibiting the cyclooxygenase/5-lipoxygenase (COX/5-LOX) pathways as such as formation of hydroxyl radicals and adhesion were prepared: 4,5-diaryl isothiazoles, 4,5-diaryl 3H-1,2-dithiole-3-thiones and 4,5-diaryl 3H-1,2-dithiole-3-ones. The aim of the present study was to develop substances which can intervene into the inflammatory processes via different mechanisms of action as multiple target non-steroidal anti-inflammatory drugs (MTNSAIDs) with increased anti-inflammatory potential. The current lead 11a was evaluated in COX-1/2, 5-LOX and ()OH scavenging in vitro assays and in a static adhesion assay where it proved to inhibit adhesion. Moreover, 11a treatment attenuated expression of macrophage adhesion molecule-1 (Mac-1) on extravasated polymorphonuclear leukocytes (PMNs) which indicates that the activation was reduced. The assays used are predictive for the in vivo efficacy of test compounds as shown for 11a in a peritonitis model of acute inflammation in mice. Thus, the novel 5-LOX/COX and ()OH inhibitor 11a possesses anti-inflammatory activity that, in addition to COX/5-LOX inhibition, implicates effects on leukocyte-endothelial interactions.
制备了三类抑制环氧化酶/5-脂氧合酶(COX/5-LOX)途径(如羟基自由基形成和黏附)的非甾体抗炎药(NSAIDs):4,5-二芳基异噻唑、4,5-二芳基-3H-1,2-二硫醇-3-硫酮和4,5-二芳基-3H-1,2-二硫醇-3-酮。本研究的目的是开发能够通过不同作用机制干预炎症过程的物质,即具有增强抗炎潜力的多靶点非甾体抗炎药(MTNSAIDs)。对当前的先导化合物11a进行了COX-1/2、5-LOX和()OH清除的体外试验以及静态黏附试验,结果证明它能抑制黏附。此外,11a处理减弱了渗出的多形核白细胞(PMN)上巨噬细胞黏附分子-1(Mac-1)的表达,这表明其活化作用降低。所使用的试验可预测受试化合物的体内疗效,如在小鼠急性炎症腹膜炎模型中对11a的试验所示。因此,新型5-LOX/COX和()OH抑制剂11a具有抗炎活性,除了抑制COX/5-LOX外,还对白细胞-内皮细胞相互作用有影响。